The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Myeloma XI trial: lenalidomide maintenance therapy for multiple myeloma
At the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, was selected to present data from the Phase III Myeloma XI trial (NCT01554852) in the oral session. This large-scale exciting trial evaluated the use of lenalidomide maintenance therapy for newly-diagnosed multiple myeloma (MM) patients, who were eligible or ineligible for stem cell transplantation. In this interview, speaking from the meeting, Prof. Jackson provides an overview of the study, its key findings and what they mean.
